Home › Companies › IBRX

ImmunityBio

Market cap $6.66B 1.06B shares (10-Q, Nov 3, 2026) × $6.26 close Nov 17, 2026

Most recent annual filing: 2026-02-23

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. QUILT-2.005 sBLA filing4Q 2026QUILT-2.005 sBLA filing, 4Q 2026, notable
  2. SRS/Altor CVR arbitration corporate updateJan 25, 2027SRS/Altor CVR arbitration corporate update, Jan 25, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (17 active programs)

Technology platforms

Cancer BioShield

First-in-class immunotherapy platform designed to restore immune competence by reversing lymphopenia; comprises cytokine fusion proteins (IL-15 superagonist ANKTIVA), adenovirus-vectored vaccines (hAd5), allogeneic and autologous NK-cell therapies (CAR-NK, M-ceNK), and additional immunomodulators; focus areas: oncology (bladder, lung, pancreatic, GBM, NHL) and infectious diseases

Targets: IL-15 receptor, PD-L1, CD19, IL-15, NK cells, CD8+ T cells, cytotoxic T cells, memory T cells, IL-15R

Capital (as filed)

Cash
$45.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$289M Sep 30, 2026
Operating cash flow
−$75.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$334M cash per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (20)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (20 calls)

Every verdict Biotech Distilled has published on ImmunityBio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Immunitybio (IBRX): Scientific Deep Dive for ANKTIVA and Pipeline Products Great science in ANKTIVA but a broken capital structure with going-concern risk and dilution overhang makes it a watch until a significant financing deal secures 18-24 months of runway.
  2. Watch Update: Is ImmunityBio (IBRX) Playing the Saudi Card? Is the Funding Gap About to Close? The Saudi summit is a setup not a solution; the dilution gap remains open until a definitive agreement with a dollar figure is announced.
  3. Speculative buy speculative UPDATE : ImmunityBio (IBRX) Secures World-First Lung Cancer Approval in Saudi Arabia. The Sandbox Strategy is Live. Saudi approval for lung cancer materially de-risks the program by providing commercial revenue potential, regulatory validation of the Phase 2 data, and a tangible asset to borrow against, reducing catastrophic dilution risk.
  4. Buy core Update: ImmunityBio (IBRX) Delivers a Trifecta of News. The Valley of Death is Filling Up with Revenue. $113M in 2025 revenue (+700% YoY), first-line bladder cancer interim data showing 84% vs 52% CR, and global regulatory arbitrage have shifted the thesis from 'show me' to 'scale me', with the dilution gap now significantly less threatening.
  5. Buy core Update: ImmunityBio (IBRX) Might Have Just Dodged a Regulatory Bullet. The Papillary Problem Getting Resolved? FDA's Type B meeting outcome requiring only additional information (no new trial) for papillary resubmission clears the last major 2025 overhang, completing a mosaic of positive news across capital, regulatory, commercial, and pipeline dimensions.
  6. Buy core Update: ImmunityBio (IBRX) Throws the Kitchen Sink at Glioblastoma. Did it Just Break the Curse? GBM data validates the ANKTIVA platform's ability to reverse lymphopenia and safely deploy off-the-shelf NK cells, reinforcing the broader IL-15 thesis underpinning the bladder and lung cancer franchises.
  7. Buy core Update: ImmunityBio (IBRX) Goes Global. The Dilution Gap Meets the Commercial Avalanche. EU approval across 33 countries, Saudi commercial launch within 60 days, and cash-efficient distributor partnerships aggressively mitigate the dilution gap while building a global commercial footprint.
  8. Buy core UPDATE: ImmunityBio (IBRX) Secures the First-Line Front. The Fundamentals Catch Up to the Hype. 700% revenue growth and a statistically significant first-line bladder cancer interim create an asymmetric entry on dips, though balance sheet fears will keep the stock volatile until the March 3 earnings call clarifies the funding bridge.
  9. Buy core UPDATE: ImmunityBio (IBRX) Closes the Papillary Loop and Flexes its Manufacturing Muscle Official FDA receipt of the papillary sBLA resubmission without a new trial, combined with a manufacturing breakthrough for off-the-shelf NK cells, systematically expands the commercial TAM and de-risks the pipeline.
  10. Buy core UPDATE: ImmunityBio (IMRX) - Unlocking the NCCN Cheat Code and Entering Asia NCCN Category 2A recommendation for papillary-only disease unlocks reimbursable TAM immediately without waiting for the FDA PDUFA, while Macau approval extends the cash-efficient regulatory arbitrage playbook into Asia.
  11. Buy core UPDATE: ImmunityBio (IBRX) - Locks the First-Line Data Deck. Enrollment Risk Eliminated. IDMC confirmation that QUILT-2.005 is adequately powered with no additional enrollment needed eliminates execution risk and reduces R&D cash burn as the trial transitions to follow-up phase.
  12. Buy core UPDATE: ImmunityBio (IBRX) - The Dilution Gap Closes, But the Founder's Mouth Opens a New One $75M non-dilutive Oberland tranche and $25M debt-to-equity conversion effectively close the dilution gap, but an FDA OPDP Warning Letter against Soon-Shiong personally for off-label promotion crystallizes the Key Man risk as a real, quantifiable liability.
  13. Buy core UPDATE: ImmunityBio (IBRX) - The 10-Q Buries Three New Lawsuits and a Washington AG Investigation Q1 revenue of $44.2M and $380.9M liquidity confirm the commercial ramp, but three new lawsuits and a Washington AG investigation all tracing to Soon-Shiong's conduct widen the founder discount and impair M&A optionality.
  14. Buy core UPDATE: ImmunityBio (IBRX) - AUA 2026 Lands the Competitive Receipts on Nadofaragene and TAR-200 Matching-adjusted indirect comparisons at AUA 2026 show ANKTIVA+BCG delivers 2.3x longer median CR duration vs. Adstiladrin and 68% fewer adverse events vs. TAR-200, incrementally strengthening the competitive moat thesis.
  15. Buy core UPDATE: ImmunityBio (IBRX) - The BCG Shortage Bear Case Just Got a Second Supplier and a Patent Fence Exclusive Tokyo-172 BCG supply deal backed by SWOG S1602 Phase 3 data and five issued combination patents through 2035 meaningfully reduce the structural BCG supply ceiling on the ANKTIVA franchise.
  16. Buy core UPDATE: ImmunityBio (IBRX) - The Papillary Loop Officially Closes FDA acceptance of the papillary sBLA with a January 6, 2027 PDUFA date, supported by the FDA's own May 18 workshop panel publicly endorsing the CIS-to-papillary extrapolation argument, puts ~85% of the NMIBC TAM formally in play for on-label conversion.
  17. Buy core UPDATE: ImmunityBio (IBRX) - The UAE Approves the Label the FDA Hasn't UAE approval of the papillary-only label and checkpoint-refractory lung indication on the same datasets under FDA review provides a second regulator's endorsement of the extrapolation argument, while updated durability data (26.6-month median CR, 54+ months ongoing) reinforces the platform thesis.
  18. Buy core UPDATE: ImmunityBio (IBRX) - The Eighth Straight Beat, and the GAAP Number That Scared Everyone Off Q2 revenue of $50.7M (+92% YoY) narrows the operating cash gap to ~$20M/quarter, the Beike arbitration was dismissed outright, and two label-expansion filings are clustered in a six-month window, while the $230M GAAP loss is overwhelmingly non-cash accounting noise.
  19. Buy core UPDATE: ImmunityBio (IBRX) - The Papillary Loop Closes Early FDA expanded ANKTIVA's label to all BCG-unresponsive NMIBC with no histology qualifier, 12 weeks ahead of the January PDUFA, based on shared biology extrapolation, retiring the single biggest regulatory risk tracked since the deep dive.
  20. Hold UPDATE: ImmunityBio (IBRX) - The Trial Wins, the Revenue Blinks The randomized first-line QUILT-2.005 trial hit its primary endpoint, but the first sequential revenue decline since launch and widening burn rate require Q4 proof that Q3 was a stocking hiccup before adding, not just holding.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (47)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 16, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)